India is burning in Covid flames. Brazil is in basically the same shape. It’s likely only a matter of time before much of Africa is in a similar situation.
This is the real reckoning.
In the US and the EU, and “rich Asia”, the story is turning to roses. But that tells the story for far less than half the world in per capita terms.
The reason that’s so problematic is because large populations of unvaccinated masses represent a breeding ground for new variants, many of which will begin before long to fall outside of the efficacy boundaries for the vaccines now protecting us in OECD nations.
The tragedy now underway in India is a reminder. As noted in the Wall Street Journal over the weekend, “India’s surge came after loosening restrictions and public complacency set in, with highly contagious variants now spreading around the globe potentially serving as an accelerant. The outbreak threatens to extend the pandemic itself, driving world-wide numbers to new highs and creating an enormous viral pool that could become a breeding ground for new and potentially dangerous mutations.”
“It is a major point of concern that more troublesome variants can emerge if left unchecked,” said Rakesh Mishra, director of the Centre for Cellular and Molecular Biology in Hyderabad, who works on genome sequencing of Covid-19 samples. “I don’t even want to imagine a more nasty variant.”
This is a key notion facing major vaccine producers such as Pfizer Inc (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA), AstraZeneca plc (NASDAQ: AZN), Novavax Inc (NASDAQ: NVAX), and Johnson & Johnson (NYSE: JNJ).
That brings Dyadic International Inc (NASDAQ:DYAI) into focus as a new approach given the transformative Dyadic C1 Protein Technology it holds as a solution that could offer a path to more rapidly and cheaply vaccinating the whole world and massively undermining the virus’s ability to conjure up new pathways to supplanting our resources for protecting human life.
The New Path
Dyadic International Inc (NASDAQ:DYAI) is set to conduct a “Fireside Chat” on Tuesday, May 4, 2021 at 10:00am Eastern Time. The fireside chat will focus on the potential of the transformative Dyadic C1 protein technology in helping meet global health challenges.
The moderated discussion will include the following Key Opinion Leaders: Alain Townsend, Ph.D. – Weatherall Institute – Oxford University, Albert Osterhaus, P.V.M, Ph.D. – Erasmus Medical Centre, Cecil Nick – Parexel (Clinical & Regulatory Support), and Joris Vandeputte – International Alliance for Biological Standardization.
According to DYAI’s recent release, the discussion will include regulatory considerations and advantages of the C1 platform, case studies describing the successful production of high value antigens for both Schmallenburg Virus and Rift Valley Fever Virus in relation to the performance in other production platforms, the efforts being undertaken by Dyadic to address the emerging SARS-CoV-2 variants including Dyadic’s development efforts advancing a SARS-CoV-2 receptor binding domain (RBD) vaccine candidate – DYAI-100 plus the rapid engineering of C1 cell lines to express known and emerging variants, the C1 platform’s potential for developing and manufacturing multi-valent COVID-19 and other subunit vaccines, including a pan-coronavirus vaccine that can protect against most or all variants, and glycoengineering C1-cells to produce mAbs and other antibodies.
As noted by the company, the conversation will be moderated by Dr. David Bramhill, a veteran in the biotechnology industry with extensive experience using a wide array of protein production technologies including E. coli, Saccharomyces cerevisiae, Pichia pastoris, Tetrahymena, Insect SF9 stable cells (not baculovirus), CHO, and HEK293.
The Big Reveal
As this presentation unfolds, it could create a splash among scientific circles because Dyadic International Inc (NASDAQ:DYAI) has something special to offer that will be covered as this process moves forward.
DYAI has developed what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1.
The C1 microorganism, technically a fungal body, enables the development and large-scale manufacture of low-cost proteins and has the potential to be further developed into a safe and efficient expression system that may help speed up the development of biologic vaccines and drugs at commercial scales, while lowering production costs and improving performance at the same time.
DYAI’s patented and proprietary C1 gene expression and recombinant protein production platform was selected by ZAPI as a production host of antigens for the Schmallenberg virus (SBV) and Rift Valley Fever virus (RVFV).
Proteins associated with vaccine production are produced through a “vector”. The baculovirus–insect cell expression system is a commonly used vector and has been extensively utilized for the production of many recombinant proteins and commercial vaccines.
However, the SBV antigen from C1 produced 300 times greater yields than the SBV antigen from baculovirus and was more stable.
Additionally, the C1 SBV antigen was shown to be safe and very effective (Full Protection) in protecting cattle and mice from the SBV. Based on these results, additional fully funded animal trials are continuing in 2021 with C1 expressed antigens for SBV and RVFV and to generate additional safety and efficacy data.
If the same results may come to apply to the crisis starting to take root in the developing world, where it will take much longer to vaccinate with current solutions at a price tag no one is likely to assume responsibility for among those who can, then it could be a game changer.
Given where DYAI shares are trading now, it’s likely that none of this potential has yet to be priced into the stock. That could potentially represent a speculative opportunity for interested investors.
DISCLAIMER: EDM Media LLC (EDM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. EDM is NOT affiliated in any manner with any company mentioned herein. EDM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. EDM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. EDM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed EDM has been compensated six thousand dollars for news coverage of the current press releases issued by Dyadic International Inc (NASDAQ:DYAI) by a third party.
EDM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and EDM undertakes no obligation to update such statements.
EDM Media LLC